A Focus on Gastrointestinal Cancers

Monday, Dec. 4, 2023 | 1-5 P.M. ESt
Live via Zoom Webinar

Join SITC and a panel of experts for an afternoon of in-depth education on all aspects of clinical implementation of immunotherapy for gastrointestinal cancers. Free for healthcare professionals, students, patients and patient advocates.

Register Now

The 2023 Advances in Cancer Immunotherapy™ educational series is supported, in part, through independent medical education grants from AstraZeneca, Bristol Myers Squibb, Exelixis, GSK, Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc. (MSD) and Novartis Pharmaceuticals Corporation.

Program Organizers

Paige Griffith, MSN, AG-ACNP, BSN
Johns Hopkins University

Suwicha Limvorasak, PharmD
Cedars Sinai Medical Center

Arsen Osipov, MD
Cedars Sinai Medical Center

Mark Yarchoan, MD
Johns Hopkins Medicine

Program Agenda

1–1:05 p.m.



1:05–1:35 p.m.


Overview of Immunotherapy and its Application for GI Cancers, Recent FDA Approvals

Michael Foote, MD – Memorial Sloan Kettering Cancer Center

1:351:55 p.m.


Landmark Clinical Trials in Upper GI Cancers

Katherine M. Bever, MD – Johns Hopkins University

1:55–2:15 p.m.


Landmark Clinical Trials in Hepatobiliary Cancers

Bridget Keenan, MD, PhD – University of California San Francisco

2:15–2:45 p.m.


Biomarkers of Response and Resistance 

Jun Gong, MD – Cedars Sinai Medical Center

2:45-3:15 p.m.


Upcoming Trials and Research in Immunotherapy for GI Cancers 

Daneng Li, MD – City of Hope

3:15–3:30 p.m.



3:304:10 p.m.


Cancer Immunotherapy in Practice: Identifying and Treating Toxicities
Laura Cappelli, MD, MHS, MS – Johns Hopkins University

Controversial Patients: IO or not? 

Aliyah Pabani, MD – Johns Hopkins Medicine

4:105 p.m.   Faculty Case Study Panel

Program Details

Target Audience

The Advances in Cancer Immunotherapy™ (ACI) programs aim to reach practicing clinical oncologists, nurses, nurse practitioners, advanced practitioners, pharmacists, emergency physicians, and other allied health professionals who wish to learn the basic principles of cancer immunotherapy and the most up-to-date clinical data for these treatments, in a multitude of disease states/therapeutic areas, in order to inform and integrate into their own clinical practice. In-training oncologists and hospital administrators will also find the program beneficial.

Case Study Submission Information

As part of the program, registrants are encouraged to submit case studies for expert review during the case study panel concluding the program. If you are interested in taking advantage of this opportunity, please review and sign the linked case study guidelines, and return your case study and signed guidelines to education@sitcancer.org.

Program Learning Objectives

  • Identify the cancer immunotherapy approaches in use for the treatment of gastrointestinal cancers.

  • Summarize recent updates in cancer immunotherapy for gastrointestinal cancers including emerging toxicities and management.

  • Implement cancer immunotherapy for gastrointestinal cancer into clinical practice appropriately.

Accreditation Information

Joint Accreditation Statement

thumbnail image In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and the Society for Immunotherapy of Cancer (SITC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC)

Successful ABIM_Logo.jpgcompletion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Continuing Medical Education

PACE designates this live activity for a maximum of 3.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

PACE designates this continuing education activity for 3.75 contact hour(s) (0.375 CEUs) of the Accreditation Council for Pharmacy Education.

Continuing Nursing Education

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 3.75 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.



Disclosure of Conflicts of Interest

PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.